This slide show highlights 2016 FDA approvals of cancer treatments, which to date include therapies for RCC, neuroendocrine tumors, Hodgkin lymphoma, CLL, sarcoma, bladder cancer, lung cancer, and breast cancer.
Ovarian Cancer Linked to Genital Talcum Powder Use
Results of the Sister Study cohort found an increased risk of ovarian cancer when enrolled patients used genital talcum powder throughout young adulthood.
Leveraging Surgical Oncology Advances in Colorectal Cancer Care
Gregory Charak, MD, discusses how modalities like laparoscopic surgery and neoadjuvant immunotherapy may benefit patients with colorectal cancer.
54 The Evaluation of Expression Levels of CXCR4, CXCL12, and LASP1 Genes in Peripheral Blood Samples of Breast Cancer Patients
Administering CAR T-Cell Therapy and Bispecific Agents in Nursing Practice
Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.
Pre-Transplant FLT3-ITD Detection Confers Relapse/Death Risk in AML
Alternative treatment strategies may be necessary for a high-risk population of patients with acute myeloid leukemia and residual FLT3-ITD.
FDA Grants Breakthrough Therapy Designation to Petosemtamab in HNSCC
Data from a phase 1/2 trial support the FDA breakthrough therapy designation for petosemtamab in recurrent head and neck squamous cell carcinoma.